KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Current Leases (2019 - 2025)

Esperion Therapeutics (ESPR) has disclosed Current Leases for 7 consecutive years, with $2.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Leases fell 13.02% year-over-year to $2.4 million, compared with a TTM value of $2.4 million through Sep 2025, down 13.02%, and an annual FY2024 reading of $2.7 million, up 76.5% over the prior year.
  • Current Leases was $2.4 million for Q3 2025 at Esperion Therapeutics, down from $2.7 million in the prior quarter.
  • Across five years, Current Leases topped out at $2.8 million in Q1 2025 and bottomed at $305000.0 in Q1 2023.
  • Average Current Leases over 5 years is $1.8 million, with a median of $2.3 million recorded in 2021.
  • The sharpest move saw Current Leases plummeted 74.94% in 2023, then skyrocketed 732.46% in 2024.
  • Year by year, Current Leases stood at $1.4 million in 2021, then crashed by 72.41% to $384000.0 in 2022, then soared by 304.43% to $1.6 million in 2023, then skyrocketed by 76.5% to $2.7 million in 2024, then fell by 13.02% to $2.4 million in 2025.
  • Business Quant data shows Current Leases for ESPR at $2.4 million in Q3 2025, $2.7 million in Q2 2025, and $2.8 million in Q1 2025.